Allergy & Immunology

Chronic Spontaneous Urticaria

Expert Roundtables Podcast: New Therapeutic Targets for the Treatment of Chronic Spontaneous Urticaria

expert roundtables by Jonathan A. Bernstein, MD; Thomas B. Casale, MD; Allen P. Kaplan, MD

Our expanding knowledge of the biology of mast cells in chronic spontaneous urticaria has helped identify novel targets to interrupt IgE signaling or affect mast cell function through IgE-independent mechanisms. In today’s podcast, our expert panel discusses promising therapeutic targets, most notably BTK and c-KIT inhibitors.

References

Alvarado D, Maurer M, Gedrich R, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022;77(8):2393-2403. doi:10.1111/all.15262

Bernstein JA, Maurer M, Saini SS. BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229-1240. doi:10.1016/j.jaci.2023.12.008

Do TT, Canty EA, Joshi SR. Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. Allergy Asthma Proc. 2023;44(1):3-14. doi:10.2500/aap.2023.44.220093

Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389-401. doi:10.1111/all.15603

Kocaturk E, Saini SS, Rubeiz CJ, Bernstein JA. Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring. J Allergy Clin Immunol Pract. 2022;10(12):3099-3116. doi:10.1016/j.jaip.2022.09.038

Zuberbier T, Peter J, Staubach P, Chularojanamontri L, Kulthanan K. Potential therapeutic approaches for chronic urticaria: beyond H1-antihistamines and biologics. J Allergy Clin Immunol Pract. 2023;11(8):2265-2273. doi:10.1016/j.jaip.2023.06.027